Objective: Monogenic defects in the interleukin-10 (IL-10) pathway are extremely rare and cause infantile-onset inflammatory bowel disease (IBD)-like pathology. Understanding how immune responses are dysregulated in monogenic IBD-like diseases can provide valuable insight in ''classical'' IBD pathogenesis. Here, we studied long-term immune cell development and function in an adolescent IL-10 receptor (IL10RA)-deficient patient who presented in infancy with severe colitis and fistulizing perianal disease and is currently treated with immune suppressants. Methods: Biomaterial was collected from the IL10RA-deficient patient, pediatric patients with IBD, and healthy controls. The frequency and phenotype of immune cells were determined in peripheral blood and intestinal biopsies by flow cytometry and immunohistochemistry. Functional changes in monocyte-derived dendritic cells and T cells were assessed by in vitro activation assays. Results: The IL10RA-deficient immune system developed normally with respect to numbers and phenotype of circulating immune cells. Despite normal co-stimulatory molecule expression, bacterial lipopolysaccharide-stimulated monocyte-derived dendritic cells from the IL10RA-deficient patient released increased amounts of tumor necrosis factor a compared to healthy controls. Upon T-cell receptor ligation, IL10RA-deficient peripheral blood mononuclear cells released increased amounts of T-cell cytokines interferon g and IL-17 agreeing with high numbers of T-bet þ and IL-17 þ cells in intestinal biopsies taken at disease onset. In vitro, the immunosuppressive drug thalidomide used to treat the patient's decreased peripheral blood mononuclear cell-derived tumor necrosis factor production. Conclusions: With time and during immunosuppressive treatment the IL10RA-deficient immune system develops relatively normally. Upon activation, IL-10 is crucial for controlling excessive inflammatory cytokine release by dendritic cells and preventing interferon g and IL-17-mediated T-cell responses.
(JPGN 2017;65: e5-e15)
What Is Known
Monogenic defects in interleukin-10 and its receptor genes IL10RA and IL10RB cause infantile-onset inflammatory bowel disease-like immunopathology with a severe phenotype that can only be treated with bone marrow transplantation. Sequence variants in the interleukin-10 gene predispose to the development of ''classical'' inflammatory bowel disease, particularly ulcerative colitis. In mice, interleukin-10 orchestrates intestinal immune homeostasis by controlling innate and adaptive immune responses. Interleukin-10 is secreted in the late phase of cellular activation and has a significant inhibitory effect on inflammatory responses.
What Is New
The immune system has developed relatively normally in an adolescent IL10RA-deficient patient receiving immunosuppressive therapy. Cytokine secretion by stimulated human dendritic cells (tumor necrosis factor a) and T cells (interferon g and interleukin-17) was elevated in the absence of a functional interleukin-10 pathway. The immune patterns uncovered from patients with IL10RA deficiency can be useful for the identification of patients with ''classical'' inflammatory bowel disease with suboptimal interleukin-10 signaling. C hronic inflammation of the gastrointestinal tract, as seen in inflammatory bowel disease (IBD), is driven by uncontrolled immune responses to commensal microbiota. Over the years, more than 160 susceptibility loci have been identified for classical IBD, some of which have led to the identification of gene polymorphisms that contribute to disease pathogenesis (1, 2) . In addition, more than 50 monogenic defects have been identified in children with earlyonset (before the age of 10 years) IBD-like gastrointestinal pathology classified as the A1a group in the Paris classification for pediatric-onset IBD (3) (4) (5) . As many of these monogenic defects fall within inflammatory immune networks that are shared by genetic variants conferring susceptibility to classical IBD, detailed analysis of patients with monogenic disorders may yield immune patterns that are useful to categorize classical IBD.
One of the key genes that clusters within the IBD susceptibility loci and monogenic disorders encodes interleukin-10 (IL-10) (3), a potent immunoregulatory cytokine essential for mounting tolerance to harmless intestinal microbial antigens. In the intestine, IL-10 is mainly produced by myeloid cells including macrophages and dendritic cells, and regulatory T cells and B cells (6) . Once secreted, IL-10 exerts its biological effects via a heterodimeric receptor complex composed of 2 IL-10 binding chains (IL-10RA) and 2 accessory chains (IL-10RB), the latter being shared with other receptors of IL-10 cytokine family members (7) . The polymorphisms in the IL-10 pathway associated with IBD (8) (9) (10) (11) and the discovery of IL10 and IL10R loss-of-function mutations causing severe, infantile-onset IBD (12) (13) (14) (15) reveal the importance of the IL-10 pathway in maintaining intestinal immune homeostasis. Identifying the mechanisms by which IL-10 exerts suppression has, however, been challenging.
With the aid of animal models, IL-10 has been recognized as a major regulator of intestinal innate and adaptive immune responses. Mice deficient in IL-10 or IL-10 receptor develop intestinal inflammation, which is dependent on bacterial colonization (16, 17) . Recent animal studies have demonstrated that IL-10 sensing by innate immune cells comprising macrophages and dendritic cells (DCs) is required for maintenance of intestinal homeostasis (18) (19) (20) . Regarding adaptive immune responses, defective IL-10 receptor signaling in memory/effector T cells renders these cells more colitogenic than wild-type cells in a mouse model of transfer colitis (21) . Although it is now widely appreciated that IL-10 orchestrates intestinal homeostasis, the precise immune cell dysfunctions resulting from a defective IL-10 pathway and their role in driving intestinal inflammation in human are only beginning to be uncovered. So far, only alterations in human macrophage differentiation and function have been described in patients with a defective IL-10 pathway (19, 22) . Functional studies in human are limited because IL10-and IL10R-deficient patients are extremely rare, with most having undergone a hematopoietic stem cell transplantation shortly after diagnosis. As genetic screening has become more accessible, it is expected that a substantial number of adolescent patients with IBD who experienced early-onset IBD will be diagnosed with a monogenic disorder. A young age of presentation and progressive disease severity can be reasons for genetic screening to detect monogenic defects that are associated with IBD-like pathology in adolescent patients (23) . Studying such adolescent patients may prove a valuable addition to identify the long-term consequences of a particular defect on immune development. Here, we studied an adolescent IL10RA-deficient patient currently treated with immune suppressants who presented with infantile IBD and was diagnosed with IL10RA deficiency at the age of 9 years. The aim of the present study was to determine the effects of an inherited defect in the IL-10 pathway on both the development and function of innate and adaptive immune cells.
METHODS

Patients
Blood was collected in ethylenediaminetetraacetic acid tubes from an IL10RA-deficient patient, cohorts of pediatric patients with IBD, age-matched healthy orthopedic patients without underlying inflammatory or intestinal disease (Table 1) , and adult healthy laboratory volunteers (age between 22 and 62 years). All patients with IBD had clinical characteristics and were diagnosed by endoscopy and histology of multiple biopsies according to the Porto criteria (24) . All participants and/or their parents gave written informed consent and the study was approved by the local ethics committee.
At the age of 9 years, a patient with IBD with infantile disease onset and from a consanguineous Turkish family was diagnosed with IL10RA deficiency through homozygosity mapping. Briefly, leukocyte DNA was hybridized to an Affymetrix GeneChip 260k Nsp1 SNP array (Santa Clara, CA). Regions of homozygosity were identified in the patient and her unaffected sister using CNAG software (version 3) (25) The exons and flanking intron regions of IL10RA were sequenced after polymerase chain reaction amplification. A single nucleotide deletion resulting in a frameshift and premature stop codon (c.585delT, p.Gly196Glufs Ã 10) was identified (Fig. 1B, C) and confirmed in an accredited diagnostic laboratory using an ABI 3730 DNA Analyzer and SeqPatient genetic analysis software (JSI Medical Systems, Ettenheim, Germany). NM_001558.3 was used as a reference sequence. A similar mutation was found in her deceased brother (confirmation on DNA isolated from paraffin embedded intestinal biopsy). IL10RA deficiency was confirmed by immunohistochemistry in colonic biopsy specimens previously taken from the patient at time of diagnosis (Fig. 1D) , and functional assays on patients' peripheral blood mononuclear cells (Fig. 1E, F) .
The currently 13-year-old girl with an IL10RA deficiency presented like other patients with mutations in the IL-10 pathway with abscesses and fissures in the perianal region in the first months of life (15, 26) . A male sibling, who had also presented with perianal disease and severe gastrointestinal symptoms, died at the age of 18 months due to a bowel perforation after colonoscopy. Colonoscopy at the age of 2 months in the female patient showed mild left-sided The patient failed to achieve full clinical remission during treatment with exclusive elemental nutrition, antibiotics, sulfasalazine, prednisone, infliximab, and methotrexate. Colchicine was started because of suspicion of Behcet disease at the age of 2 years. The patient's medical record timeline is shown in Figure 1A . Until now, the family has refused hematopoietic stem cell transplantation, because of the risk of the procedure in relation to the relatively mild clinical course. Currently, she has only occasionally had clinically mild gastrointestinal symptoms since the age of 3 while receiving thalidomide and intravenous immunoglobulin. Fecal calprotectin is only mildly elevated (151 mg/g, normal values in patients with IBD <100 mg/g). Respiratory infections, that were severe from the age of 2 years, have decreased since the start of monthly intravenous immunoglobulins, as advised by the immunology/infectiology team. Between the ages 9 until 13 blood was repeatedly collected from the IL10RA-deficient patient before her monthly intravenous immunoglobulins infusion. At the time of the experiments the patient had no physical complaints.
Flow Cytometry
Whole blood samples were lysed and stained with antibodies directed against CD11c and ionomycin (0.5 mg/mL, Sigma-Aldrich) in the presence of Brefeldin A (3 mg/mL eBioscience) for the last 3 hours. Cells were stained with anti-CD3 (BD Biosciences), fixed in 2% formaldehyde, permeabilized with saponin (Sigma-Aldrich), and labeled with anti-IL-21 (eBio3A3-N2; eBioscience), anti-IL-17A (eBio64DEC17; eBioscience), anti-interferon gamma (anti-IFNg) (4SB3, BD Biosciences), or appropriate isotype controls (eBioscience). Foxp3 was stainedusing theFoxp3 Staining Buffer Set (eBioscience)according to manufacturer's protocol. Cells were analyzed using the FACSCanto II (BD Biosciences) and FlowJo software.
Cell Isolation and Culture
Cells were cultured in Iscove's modified Dulbecco's medium (Life Technologies, Grand Island, NY) supplemented with heat inactivated fetal calf serum, Glutamax (Life Technologies), 2-mercaptoethanol, penicillin, and streptomycin. Peripheral blood mononuclear cells were isolated using a Ficoll-Hypaque gradient and stimulated with purified lipopolysaccharide from Escherichia coli Serotype 0111:B4 (100 ng/mL, Sigma-Aldrich) or anti-CD3 (500 ng/mL; Sanquin, Amsterdam, The Netherlands) with or without IL-10 (25 ng/mL, R&D Systems) or thalidomide (1, 10 mg/mL, Celgene Corp., Odenton, MD) for the indicated time-points. CD14 þ monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Purified monocytes (>90%) were differentiated into monocyte-derived dendritic cells (moDCs) during a 6-day culture with 800 U/mL GM-CSF (Novartis, Basel, Switzerland) and 400 U/ mL IL-4 (R&D). At day 6, lipopolysacchoride (LPS) was added to the wells in the presence or absence of IL-10. Supernatants were collected at day 7.
Measurement of Cytokines in Cell Culture Supernatant
Cytokine production was measured in cell culture supernatants using enzyme-linked immunosorbent assays for tumor necrosis factor alpha (TNFa) (BD Biosciences, Breda, The Netherlands), IFNg (eBiosciences), or IL-17A (Duoset; R&D Systems) or by application of the standard protocol of the Human Inflammation Cytometric Bead Array specific for IL-8, IL-1b, IL-6, IL-10, TNF, and IL-12p70 (BD Biosciences).
Immunohistochemistry on Paraffin Sections
Paraffin-embedded biopsies were sectioned, deparaffinized, and endogenous peroxidase activity was quenched with 3% H 2 O 2 in PBS for 20 minutes. Antigen retrieval was performed by microwave treatment in citrate buffer (10 mmol/L, pH 6.0) or enzymatic treatment with 0.1% pepsin. The sections were blocked for 1 hour in 10% normal human serum plus 10% normal goat, rabbit, or horse serum diluted in 10 mmol/L Tris, 5 mmol/L ethylenediaminetetraacetic acid, 0.15 mol/L NaCl, 0.25% gelatin, and 0.05% Tween-20, pH 8. Antibody incubation was performed overnight at 48C using anti-IL-10RA (polyclonal rabbit, Millipore, Temecula, CA), anti-CD3 (polyclonal rabbit, DakoCytomation, Glostrup, Denmark), anti-IL-17A (polyclonal goat IgG; R&D Systems, Abingdon, UK), anti-IL-21 (polyclonal rabbit IgG, Lifespan Biosciences, Seattle, WA), anti-Foxp3 (mouse IgG 1 clone 236A/E7, eBioscience), anti-T-bet (mouse IgG clone 4Bio, eBioscience), or proper isotype control antibodies. Immunoreactive sites were detected with biotinylated secondary antibodies using the Vectastain ABC Elite Kit (Vector Laboratories, Burlingame, CA) and 3,3'-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, Zwijndrecht, The Netherlands). Tissues were counterstained with hematoxylin (Vector Laboratories). Images were acquired using a Leica DM5500B upright microscope and LAS image acquisition software (Leica Microsystems, Rijswijk, The Netherlands).
Statistical Analysis
Significance was determined using student's t test or Mann-Whitney U test performed on GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA). P values of <0.05 were regarded as significant.
bowel disease (IBD) using an antibody raised against the cytoplasmic domain of human IL-10RA (residues 257-278). E, Control or patient whole blood was stimulated with IL-10 (25 ng/mL) for 15 minutes or IL-6 (100 ng/mL) for 30 minutes, and STAT3 phosphorylation (Tyr 705 ) was quantified by flow cytometry. Gated on monocytes for IL-10 stimulation or the whole cell population for IL-6 stimulation. F, Control and patient peripheral blood mononuclear cells were stimulated with LPS (100 ng/mL) in the absence or presence of IL-10 (25 ng/mL). After 6 hours, supernatants were collected and TNFa secretion was measured by ELISA. IL ¼ interleukin; TNF ¼tumor necrosis factor. Ã P < 0.05.
RESULTS
Normal Distribution of Circulating Dendritic Cells and T-cell Subsets in the IL10RA-deficient Patient During Treatment
Primary immunodeficiency caused by monogenic defects often leads to abnormal immune cell development, cellular dysfunction, or both. To determine whether an inherited defect in the IL-10 pathway causes abnormal immune cell development, we determined the frequency of the major circulating immune cell populations in the IL10RA-deficient patient during adolescence. While in remission, the percentages of circulating CD11c þ HLA-DR þ DCs ( Fig. 2A) , CD4 þ and CD8 þ T cells (Fig. 2B ) of the patient were within the normal range for pediatric patients with IBD (in remission or with active disease) and age-matched orthopedic patients. Similarly, the frequency of Foxp3 þ cells within the CD4 þ T-cell population was comparable between the IL10RA-deficient patient and pediatric patients with IBD and pediatric controls (Fig. 2C) . To investigate changes in circulating mucosal CD4 þ T cells in particular, we analyzed the combined cell-surface expression of CD62L neg and CD38 and the gut-homing marker CCR9 within the CD4 þ T cell population (27, 28) . Both the percentages of circulating CD4 þ
CD62L
neg CD38
þ cells and gut-homing CD4 þ CCR9 þ cells were not different to pediatric controls or pediatric patients with IBD (Fig. 2D) . Moreover, no differences were observed for
neg cells, and CD4
. Consistent with the unchanged T-cell frequencies, the percentages of CD3 þ T-cell subpopulations producing the effector cytokines IL-17, IFNg and IL-21 were comparable to pediatric patients with IBD in remission (Fig. 2E) . Thus, in the absence of a functional IL-10 pathway, during treatment with thalidomide, colchicine, and intravenous immunoglobulins the immune system has developed with normal frequencies of CD11c þ HLA-DR þ DCs and circulating effector memory T cell subsets.
Functional Consequences of Defective IL-10 Signaling on Monocyte-derived Dendritic Cells
The functional impact of primary immunodeficiency on innate and adaptive immunity helps to elucidate underlying mechanisms of disease. Recent evidence from animal studies demonstrates that loss of IL-10R expression by innate immune cells causes severe colitis (18) (19) (20) . Therefore, we investigated whether alterations in the in vitro generation and function of DCs, as part of the innate immune system, occur in the absence of a functional IL-10 pathway. Monocytes from the IL10RA-deficient patient differentiated normally into DCs in response to GM-CSF and IL-4. As expected (29) , LPS-induced upregulation of co-stimulatory molecules was inhibited by exogenous IL-10 in healthy control moDCs, but not in IL10RA-deficient moDCs. Post stimulation, expression levels of HLA-DR and the costimulatory molecules CD40, CD80, and CD86 were comparable between the IL10RA-deficient moDCs and healthy control moDCs (Fig. 3A) . In contrast, significantly higher amounts of TNFa were released by LPS-stimulated IL10RA-deficient moDCs, while IL-10 production was similar to healthy control moDCs (Fig. 3B ). Comparable to that observed for TNFa, IL10RA-deficient moDCs released higher amounts of the chemotactic cytokine CXCL-8 in response to LPS (data not shown). These data demonstrate that IL10RA-deficient moDCs develop normally and do not hyper-express co-stimulatory molecules, but when stimulated with LPS, these cells secrete significantly more proinflammatory cytokines.
IL-10 Fails to Suppress Effector T-cell Responses in the IL10RA-deficient Patient
Considering that DCs are potent inducers of primary T-cell immune responses and that IBD is mediated by abnormally activated effector T cells predominantly secreting IFNg and IL-17 (30), we next investigated whether the IL10RA-deficient patient exhibits alterations in effector T-cell responses. IL-10 inhibited secretion of the effector T cell cytokines IFNg and IL-17 by anti-CD3-stimulated peripheral blood mononuclear cells from healthy controls (Fig. 3C) . Interestingly, upon anti-CD3 stimulation, peripheral blood mononuclear cells from the IL10RA-deficient patient secreted significantly enhanced amounts of IFNg, and to a lesser extent IL-17, which could not be inhibited by exogenous IL-10 (Fig. 3C) . To ascertain whether these effector T-cell cytokines or the transcription factor critical for their production had possibly played a role in patients' colitis, we performed immunohistochemical analysis of paraffin-embedded biopsies obtained from the IL10RA-deficient patient at disease onset. At the age of 2 and 10 months, descending colon tissue showed an influx of lamina propria and intraepithelial CD3 þ cells (Fig. 4A-C) . Co-staining of serial sections revealed that the majority of the CD3 þ cells co-localized with IL-21
þ , and/or T-bet þ cells in the inflamed mucosa (Fig. 4C ). For comparison, descending colon tissue of an agematched (5 months old) non-IBD patient suffering from cow's milk protein intolerance is shown (Fig. 4D) . Foci of Foxp3 þ cells were detected in the intestinal mucosa lesions, suggesting that the intestinal inflammation is not simply a consequence of defective Foxp3 þ T cell recruitment. In conclusion, these data demonstrate that IL-10 is essential for suppressing IFNg and IL-17-secreting effector T cells, and that in the absence of a functional IL-10 pathway, inflammatory lesions in the colon contain both effector T cell subsets.
Thalidomide Inhibits LPS-mediated TNFa Production But Not Anti-CD3-driven IFNg and IL-17 Production by Peripheral Blood Mononuclear Cells
Given that IL-10R signaling is crucial for controlling the function of moDCs and cytokine secretion by effector T cells, we next addressed the effect of the patient's current therapy on both innate and adaptive immune responses in vitro. Since treatment with thalidomide primarily promoted clinical remission of the intestinal symptoms in the IL10RA-deficient patient, we developed an in vitro assay system in which we studied the effects of thalidomide on innate and adaptive immune responses to bacterial LPS and T-cell receptor ligation, respectively. Thalidomide treatment had no significant effect on anti-CD3-mediated IFNg and IL-17 cytokine secretion by peripheral blood mononuclear cells from healthy controls (Fig. 5A, C) and the IL10RA-deficient patient (Fig. 5B, D) . Thalidomide, however, significantly decreased TNFa production by LPS-stimulated peripheral blood mononuclear cells from both healthy controls (Fig. 5E ) and the IL10RA-deficient patient (Fig. 5F) . PBMC from the IL10RA-deficient patient seemed less sensitive to the effects of thalidomide, possibly because the cells have already been exposed to this drug in the patient. Altogether, these results suggest that inhibition of innate responses may contribute to disease suppression.
DISCUSSION
We investigated the long-term effect of a defective IL-10 pathway on immune system development and function in an During treatment, the number of circulating CD11c þ DCs was normal in the IL10RA-deficient patient, indicating sufficient bone marrow output and differentiation of the myeloid cell lineage. DCs generated in vitro from peripheral blood monocytes showed normal upregulation of MHCII and co-stimulatory molecules but when stimulated with a bacterial stimulus, IL10RA-deficient moDCs secreted significantly higher amounts of TNFa. The in vitro generation of functional DCs occurred independently from any confounding effects of ongoing intestinal inflammation or drug therapy, suggesting a cell-intrinsic effect of IL10R deficiency on proinflammatory cytokine production by these cells. The differential regulation of co-stimulatory molecule expression and cytokine production is notable, as previous neutralization studies proposed a role for IL-10 in both autocrine co-stimulation and cytokine release (31, 32) . Our data are however, in line with observations in CD11c þ -specific Il10r-deficient mice, in which only cytokine release and not co-stimulatory molecule expression by CD11c þ cells was affected (33) . In our study, cytokine production by cells of the IL10R-deficient patient was compared to those from adult healthy volunteers. Cytokine production may differ between children and adults. It has, however, been shown that in healthy children, cytokine production by PBMC is lower compared to adults upon mitogen and antigen stimulation (34) . Therefore, the degree with which the cytokine production by cells from the IL10RA-deficient patient is enhanced may be an underestimation.
Similar as observed for DCs, the composition of T-cell subpopulations in peripheral blood did not differ between the IL10RA-deficient patient and pediatric controls and pediatric IBD patients. This is of interest as IL-10 has been proposed to act as a cofactor for thymocyte proliferation (35) . Consistent with prior findings (36) , exogenous IL-10 inhibited IFNg and IL-17 secretion by in vitro-activated peripheral blood mononuclear cells from control subjects. Reciprocally, in the IL10RA-deficient patient an enhancement in IFNg/T-bet and IL-17 expression was seen in mucosal tissue and peripheral blood mononuclear cells. In mice, T helper 17 (T H 17) cells, but not IFNg-producing T helper type 1 (Th1) cells, express a functional IL-10 receptor and are sensitive to the IL-10 inhibitory effects (37) . In addition to a direct effect, IL-10 signaling in regulatory T cells has also been implicated in limiting pathogenic T H 17 cell responses (38) . Moreover, several groups have demonstrated that especially IL-10 sensing by innate immune cells is required for suppression of T cell-driven intestinal inflammation (18) (19) (20) . Whether IL-10 regulates human IFNg and IL-17-secreting T cells directly or indirectly via innate immune cells or by favoring Treg cell-mediated suppression awaits further studies.
The observed inhibitory effect of thalidomide on TNFa production by LPS-stimulated IL10RA-deficient peripheral blood mononuclear cells suggests that the inhibition of TNFa secretion contributes to suppression of innate responses and may be involved in the clinical remission of the intestinal symptoms. As the patient failed to respond to infliximab, mechanisms other than TNFa inhibition may have, however, contributed to disease control. Thalidomide is known to inhibit NF-kB activity (39) and activation of caspase-1 and thereby secretion of biologically active IL-1b protein (40) . As thalidomide suppresses IL-12 production by human monocytes (41) , it is tempting to speculate that thalidomide may be effective in inhibiting Th1 cytokine responses. Moreover, thalidomide binds cereblon, an upstream regulator of interferon regulatory factor 4 (42, 43) . Interferon regulatory factor 4 is an important regulator of T H 17 cells, and Irf4-deficient mice display reduced Il17 gene expression during chronic intestinal inflammation (44) . Although thalidomide had no effect on IFNg and IL-17 production in vitro, we cannot exclude an effect of thalidomide on T cells in vivo. IL10RA-deficient patient Healthy control The abnormalities caused by monogenic defects in IBD-like disease hold valuable knowledge on the mechanisms that may predispose to ''classical'' IBD. Our findings show that IL10R deficiency has a major effect on the cytokine secretion by human moDCs (TNFa) and T cell cytokine production (IFNg and IL-17), suggesting that these defects may contribute to the clinical manifestation of the IBD-like gastrointestinal pathology. Although the primary limitation of the present study is that it involves only 1 IL10RA-deficient patient, we expect similar results in other patients with defects in the IL-10 pathway. In addition to moDCs and T cells, it has been recently reported that monocyte-derived macrophages from IL10R-deficient patients secrete significantly more proinflammatory cytokines (19) . Interestingly, the biological process term ''regulation of cytokine production'' is significantly enriched among the 163 IBD susceptibility loci, and further detailed analysis showed an enrichment for genes expressed especially by DCs and to a lesser degree CD4 þ T cells (2) . These and our findings underscore the importance of aberrant activated innate immune cells and CD4 þ T cells in IBD pathology. The identified immune abnormalities in monogenic disease may be useful for the functional understanding and classification of polygenic classical IBD phenotypes. It can be envisaged that a subgroup of patients with IBD may exhibit milder forms of IL-10 deregulation. Future studies will focus on the immunological alterations in IL10R-deficient patients and uncover biomarkers and immune assays to identify individuals with suboptimal IL-10 signaling among polygenic classical IBD patients.
Collectively, our data provide fundamental insights into the immune system development and functions in an IL10R-deficient patient. Our findings promote our knowledge of intestinal immune regulation, which is required to advance our ability to classify the varying clinical pathologies of IBD.
